

The Response

The Examiner has required restriction to one of the following inventions:

- I. Claims 1-24, and 28, drawn to a method for inducing a psoriasis-like syndrome in an animal by transferring a purified CD45Rb positive T cell population, an immunodeficient mouse induced to exhibit a psoriasis-like syndrome, and a method for screening a candidate therapy for efficacy in treatment of psoriasis.
- II. Claims 25-27, drawn to a method treating a patient suffering from psoriasis using antibody.

In response to the Restriction Requirement, Applicants hereby elect the invention of group II, Claims 25-27. Applicants expressly reserve the right to prosecute claims directed to the remaining allegedly distinct groups in one or more continuing or divisional applications.

The Examiner also requests Applicants to elect one species among interferon gamma, interleukin 12, E-selectin, P-selectin, CD3, and alphaE integrin subunit, for examination practice. Applicants are hereby electing interleukin 12 for examination practice. Applicants understand that upon the allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR §1.141.

Claims 25, 26 and 33-44 are readable thereon the elected species.

CONCLUSION

Applicants believe that the application is in good and proper condition for allowance. Early notification of allowance is earnestly solicited. If, in the opinion of the Examiner, a

telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 463-8109.

Respectfully submitted,



Date: August 30, 2002

A handwritten signature in dark ink, appearing to read 'Albert P. Halluin', is written over a horizontal line.

Albert P. Halluin (Reg. No. 25,227)

Viola T.Kung (Reg. No. 41,131)

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue, Box 34
Menlo Park, CA 94025
(650) 463-8109



Application No.: 09 857,823
Attorney Docket No.: 05882.0003.PCUS00

MARKED-UP VERSION TO SHOW CHANGES MADE TO SPECIFICATION


RECEIVED

In the Title

SEP 05 2002

Page 1, lines 1-2, delete "ANIMAL MODEL FOR PSORIASIS FOR THE
PREVENTION AND TREATMENT OF PSORIASIS IN HUMANS" and insert --METHOD OF
TREATING PSORIASIS--.

TECH CENTER 1600/2900



MARKED-UP VERSION TO SHOW CHANGES MADE TO CLAIMS

RECEIVED

SEP 05 2002

TECH CENTER 1600/2900

In the Claims

Cancel Claims 1-24 and 28-32.

25. (Amended) A method of treating a patient suffering from psoriasis comprising the step of administering to the patient an antibody that binds to an antigen selected from the group consisting of interferon gamma, interleukin 12, [E-selectin, P-selectin, CD3 or] and alphaE integrin subunit.

26. (Amended) [A] The method of Claim 25, wherein said antibody is a humanized antibody.

27. (Amended) [A] The method of Claim 26, wherein said antibody is the HuZAF [, HuEP5C7, or HuM291] antibody.

Add the following new claims.

--33. (New) The method according to Claim 25, wherein said antibody is an anti-interleukin 12 antibody.

34. (New) The method according to Claim 33, wherein said antibody is in an amount effective to block the effect of interleukin 12.

35. (New) The method according to Claim 33, wherein said anti-interleukin 12 antibody is a monoclonal antibody.

36. (New) The method according to Claim 35, wherein said monoclonal antibody has a binding affinity of at least 10^8 M.

37. (New) The method according to Claim 35, wherein said monoclonal antibody is a chimeric monoclonal antibody or a humanized monoclonal antibody.
38. (New) The method according to Claim 37, wherein said monoclonal antibody is 5F2, 16F2, 16 G2, or 20E11 in a chimeric or humanized form.
39. (New) The method according to Claim 33, wherein said pharmaceutical formulation is administered to a patient orally, topically, subcutaneously, intramuscularly, or intravascularly.
40. (New) The method according to Claim 33, wherein said anti-interleukin 12 antibody is administered in a dose of 0.01-100 mg/kg body weight.
41. (New) The method according to Claim 40, wherein said anti-interleukin 12 antibody is administered in a dose of 0.1-10 mg/kg body weight.
42. (New) The method according to Claim 33, wherein said treatment reduces PASI by at least 50%.
43. (New) A method of treating a patient suffering from psoriasis comprising the step of administering to a patient a pharmaceutical formulation comprising an interleukin 12 receptor or its binding subunit that binds to interleukin 12.
44. (New) The method according to Claim 43, wherein said interleukin 12 receptor or its binding subunit is recombinantly linked to the Fc region of a human immunoglobulin.--